CTRI/2024/05/066650尚未招募3 期
Three arm clinical study to evaluate the efficacy of sidharthak raskriya topically siddharthak kashaya orally and both combined together in ekkustha with special reference to psoriasis - NI
Dr abhijeet sureshrao bhendekar0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with clinical features of eka-kustha having signs and symptoms namely kandu ( itching), shushkta, vaivarnya( depigmentation), mastyashakalopama( silvery patch skin)
- •patients of both gender male and female, irrespective of of caste and sccioeconomic status.
排除标准
- •Patient suffering from any chronic skin disease, immmune suppressed systemic disorder.
- •patient suffering from any other systemic disorder like tuberculosis, diabetes mellitus , HBsAg positive and know case of leprosy.
- •pregnant and lactating woman
- •Psoriatic arthritis.
研究者
相似试验
进行中（未招募）
不适用
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymusEUCTR2011-002872-17-DKovartis Pharma Services AG124
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymusEUCTR2011-002872-17-DEovartis Pharma Services AG124
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymusEUCTR2011-002872-17-ESovartis Farmacéutica S.A.105
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymusEUCTR2011-002872-17-SEovartis Pharma Services AG124
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymusEUCTR2011-002872-17-ITOVARTIS FARMA124